GALECTIN THERAPEUTICS INC 8-K

What Happened

• Galectin Therapeutics Inc. announced in a Form 8-K filed January 21, 2026 that on January 16, 2026 its board, at the compensation committee’s recommendation, approved cash retention bonuses for two senior officers. Dr. Khurram Jamil, the Chief Medical Officer, will receive a $300,000 retention bonus and Jack Callicutt, the Chief Financial Officer, will receive a $150,000 retention bonus.
• The bonuses are payable in three equal installments on June 1, 2026, September 1, 2026 and December 1, 2026, and must be repaid if the officer voluntarily resigns without good reason or is terminated for cause prior to December 31, 2026, per their employment agreements.

Key Details

• Officers: Dr. Khurram Jamil (CMO) and Jack Callicutt (CFO).
• Bonus amounts: $300,000 (CMO) and $150,000 (CFO).
• Payment schedule: three equal cash payments on June 1, Sept 1, and Dec 1, 2026.
• Clawback condition: repayment required if voluntary resignation without good reason or termination for cause before Dec 31, 2026.

Why It Matters

• For investors, this filing signals the company is taking steps to retain key executives through the end of 2026, which can be important for continuity in clinical and financial leadership.
• It represents a near-term cash commitment spread over 2026 and includes repayment protections if the executives leave for reasons the company deems their responsibility.
• The 8-K does not report any other officer departures or elections.